WHEN YOU ARE UNCERTAIN OF HER ER/PR STATUS...GIVE HER ANOTHER CHANCE.
MORE THAN 20% OF WOMEN'S ER/PR STATUS MAY BE MISCLASSIFIED1-4
Inaccurate results may impact treatment decisions, eliminate potentially efficacious therapies or subject patients to therapies known to cause serious adverse events.
|Authors||Journal||Publication Year||Marker Discussed||Misclassification Rate|
|Allred DC3||The Oncologist||2008||ER/PR||30%|
|Hammond ME4||Journal of Clinical Oncology||2010||ER/PR||20%|
Table 1. Peer-reviewed literature shows that conventional IHC-based technology can misclassify ER/PR receptor status.
EXPECT ACCURATE AND REPRODUCIBLE RESULTS
NexCourse BCa by AQUA technology is quantitative IHC, providing an accurate and quantitative score for protein expression.
- More reproducible than routine IHC testing5
- Minimizes false-negative results by utilizing an objective, quantified score for protein expression5
- Ideal for confirmatory testing of ER/PR status prior to hormonal and/or chemotherapy
- Only commercial laboratory to offer AQUA technology
RECONFIRM ER/PR STATUS BEFORE YOU TREAT
Patients identified as ER+ by automated quantitative analysis (AQUA), but ER- by routine IHC, demonstrated similar prognostic outcomes to patients identified as ER+ by both.5
AQUA TECHNOLOGY DEMONSTRATES A HIGHER DEGREE OF CORRELATION
AQUA technology combines the benefits of fluorescent microscopy and automated image analysis with clinically validated antibodies to compute quantitative results.
Genoptix® and NexCourse® are registered trademarks of Genoptix, Inc.
AQUA® is a registered trademark of HistoRX, Inc.